Tilray (NASDAQ:TLRY) is a licensed producer based in BC, Canada.

The company cultivates, processes and distributes cannabis to countries including Germany, the Czech Republic, Croatia, Cyprus, Chile, Argentina, Australia, New Zealand and Canada.

Founded in 2013, Tilray produces a variety of medical cannabis products, including flower strains, oils and capsules. It also sells accessories ranging from vaporizers to vaping pens to holders to rolling trays.

The company is majority owned by Privateer Holdings, whose CEO, Brendan Kennedy, is also CEO of Tilray. Tilray is in good company under Privateer Holdings’ umbrella — the American holdings firm also owns Leafly and Marley Natural.

Leafly is a widely used cannabis information website, and Marley Natural is a cannabis line that is branded with Bob Marley’s image. Marley Natural sells cannabis strains as well as paraphernalia.

On July 9, 2018, Tilray launched on the NASDAQ, making it the first cannabis stock to complete an IPO on the US exchange. Its share price has since shot up, dwarfing giants Aurora Cannabis (TSX:ACB) and Aphria (TSX:APH); Tilray is now competing with Canada’s other top producer, Canopy Growth (TSX:WEED), for the highest price point.

While Tilray’s market cap is nowhere near its annual revenue, investors are pleased to have seen stronger and stronger financial reports each quarter, lending to sentiment that the firm is steadily filling the industry’s high expectations.

Despite being listed on the NASDAQ, Tilray is not currently able to sell in the US due to federal laws that classify marijuana as a Schedule 1 drug. Until national legalization occurs in the US, Tilray will bide its time and continue selling in the various other countries listed above.

Don’t forget to follow us @INN_Cannabis for real-time updates!

Securities Disclosure: I, Amanda Kay, hold no direct investment interest in any company mentioned in this article. 

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less